The Registry of Oncology Outcomes Associated With Testing and Treatment
This study is to collect and validate regulatory-grade real-world data (RWD) in oncology using the novel, Master Observational Trial construct. This data can be then used in real-world evidence (RWE) generation. It will also create reusable infrastructure to allow creation or affiliation with many additional RWD/RWE efforts both prospective and retrospective in nature.
Checked against the public recordLast updated Dec 18, 2024 · Source: ClinicalTrials.gov
What this study is about
- Purpose
- Not specified
- Study type
- Observational
- Phase
- Not applicable
- Sponsor
- Taproot Health
- Interventions being studied
- Diagnostic Test: Biomarker Testing (L); Drug: Systemic Treatment (T); Other: Patient Reported Outcomes (P)
How this study is categorized
These labels come from structured fields and exact terms in the public record.
Who may be able to participate
Inclusion Criteria: * Patient or representative provides written informed consent * Patient is diagnosed with advanced malignancy * Patient is willing to be treated for this malignancy according to a plan determine by them and their physician * patient will be willing to have regular follow up visits as part of their standard of care Exclusion Criteria: * patient is not a candidate or does not desire any treatment for their disease
Important: This is the sponsor’s public criteria, not a determination of eligibility. The study team must review your individual situation.
U.S. locations
- Teton Cancer InstituteIdaho Falls, Idaho
- Oncology and Hematology of South TexasLaredo, Texas
Source and freshness
Processed from ClinicalTrials.gov. Last public update: Dec 18, 2024. Always confirm current availability with the study team.